Makers of generic drugs in India faced an uncertain new playing field on Wednesday after the approval of a bill that would bring India into line with international patent law -- over time.
The bill, which requires only the signature of President A.P.J. Abdul Kalam, will set an unspecified ''reasonable royalty'' on drugs that are patented. What precisely that will cost India's consumers and companies remains to be seen.
